Related Experiment Videos
Blocking of mononuclear cell activation by lonazolac
International Journal of Tissue Reactions
|January 1, 1985
Summary
Lonazolac, a new nonsteroidal anti-inflammatory drug, was found to block mononuclear cell activation in arthritis. Prostaglandin E2 reversed this effect, suggesting lonazolac modulates immune responses.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage arthritis symptoms.
- The immunological effects of NSAIDs on mononuclear cell activation require further investigation.
Purpose of the Study:
- To investigate the immunological effect of lonazolac on mononuclear cell activation in the context of arthritis.
- To determine if lonazolac modulates the immune response in arthritic conditions.
Main Methods:
- The indirect Leukocyte Adherence Inhibition Test was employed.
- Mononuclear cells from arthritis patients were exposed to synovial stimuli.
- The effect of lonazolac and prostaglandin E2 on cell adherence was measured.
Main Results:
- Very low concentrations of lonazolac abolished the mononuclear cell response to synovial stimulus.
- The inhibitory effect of lonazolac was completely reversed by the addition of prostaglandin E2.
Conclusions:
- Lonazolac demonstrates an ability to block mononuclear cell activation in arthritis.
- Lonazolac appears to modulate the immune response, with prostaglandin E2 playing a role in reversing its effects.